The Board of Directors of Orion Corporation has elected the following persons to the Nomination Committee of the company:
Kari Jussi Aho
Matti Kavetvuo
Timo Ritakallio
Seppo Salonen
Hannu Syrjänen
Jukka Ylppö
Matti Kavetvuo was elected Chairman of the Committee.
The Committee prepares and presents a recommendation to the Board of Directors for the proposal to the Annual General Meeting concerning the composition of the Board. The term of the Nomination Committee shall end at the closing of the next Annual General Meeting of the company.
The essentials of the working order of the Nomination Committee and a description of the election process of its members are provided at http://www.orion.fi/board-committees, a page in the Corporate Governance section of the Orion Group internet website.
Orion Corporation
| Timo Lappalainen President and CEO | Olli Huotari SVP, Corporate Functions |
Contact person:
Timo Lappalainen, President and CEO, phone +358 10 426 3692
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi
Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.
The Group's net sales in 2010 amounted to EUR 850 million. The Company invested EUR 85 million in research and development. At the end of 2010, the Group had a total of approximately 3,100 employees, of whom 2,450 worked in Finland and 650 in other countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.